Iv Infusion Articles & Analysis
5 news found
Kurve Therapeutic’s patented intranasal drug delivery technology, Controlled Particle Dispersion® (CPD), has been shown to bypass the blood-brain barrier, delivering 30x more medication directly to the brain than infusions. Marc Giroux, Kurve Therapeutics CEO and founder said: “An IV infusion manages to deliver one-tenth of 1% ...
In preliminary studies, Kurve’s patented Controlled Particle Dispersion® technology has been shown to bypass the blood-brain barrier and was able to deliver up to 30x more medication directly to the brain than infusions. ” An IV infusion manages to deliver one-tenth of one percent through the BBB. ...
Escalating doses of AFM24 will be given to each cohort as weekly intravenous (IV) infusions. The starting dose and at least two planned dose escalations are based on results from the ongoing AFM24 monotherapy trial. Atezolizumab is given at a fixed dose of 840 mg biweekly IV infusion. Patients will receive AFM24 and atezolizumab ...
Today, the administration of irinotecan is intravenous (IV) bolus infusions, typically as a high dose every third week. Oncoral is a novel patented tablet formulation of irinotecan for daily dosing at home with potential to offer better patient outcomes. ...
AVM0703 is a high-concentration and high-volume formulation of dexamethasone sodium phosphate (DSP) for intravenous (IV) infusion. This proprietary formulation does not contain dose-limiting excipients such as benzyl alcohol and parabens found in generic formulations and could possibly be used at up to 21 mg/kg per dose. AVM0703 is administered as a single ...